Trends in risk factor prevalence and management before first stroke: Data from the South London stroke register 1995-2011

Stroke

Volumn 44, Issue 7, 2013, Pages 1809-1816

  Marshall, Iain J ^a   Wang, Yanzhong ^a,b   McKevitt, Christopher ^a   Rudd, Anthony G ^a,b   Wolfe, Charles D A ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b BHF Centre for Regenerative Medicine and BHF Centre of Excellence and the Biomedical Research Centre at Guy s St Thomas NHS Foundation Trust and King s College London   (United Kingdom)

Author keywords

primary prevention ? stroke ? stroke epidemiology

Indexed keywords

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; ETHNICITY; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK;

PRIMARY PREVENTION; STROKE; STROKE EPIDEMIOLOGY;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; AGED; AGED, 80 AND OVER; DRUG PRESCRIPTIONS; EARLY DIAGNOSIS; FEMALE; HUMANS; LONDON; MALE; MIDDLE AGED; PREVALENCE; REGISTRIES; RISK FACTORS; SEX FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879954990     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.000655     Document Type: Article

References (38)

1. WHO. Cardiovascular diseases (CVDs) factsheet. WHO website. http:// www.who.int/mediacentre/factsheets/fs317/en/index.html. Accessed January 7, 2013
2. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev. 2009;CD001841
3. Cholesterol Treatment Trialists Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-Analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-590
4. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2009;CD001927.
5. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22:11-19
6. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003;290:2685-2692
7. Cruz-Flores S, Rabinstein A, Biller J, Elkind MSV, Griffith P, Gorelick PB, et al. Racial-Ethnic Disparities in Stroke Care: The American Experience. Stroke 2011;42:2091-116
8. Pears E, Hannaford PC, Taylor MW. Gender, age and deprivation differences in the primary care management of hypertension in Scotland: a cross-sectional database study. Fam Pract 2003;20:22-31
9. WHO. Adherence to long-term therapies: evidence for action. WHO website. http://www.who.int/chp/knowledge/publications/adherence- report/en/index.html. Accessed January 7, 2013
10. Sacco RL, Boden-Albala B, Abel G, Lin IF, Elkind M, Hauser WA, et al. Race-ethnic disparities in the impact of stroke risk factors: the northern Manhattan stroke study. Stroke 2001;32:1725-1731
11. Hajat C, Dundas R, Stewart JA, Lawrence E, Rudd AG, Howard R, et al. Cerebrovascular risk factors and stroke subtypes: differences between ethnic groups. Stroke 2001;32:37-42
12. Bravata DM, Wells CK, Gulanski B, Kernan WN, Brass LM, Long J, Concato J. Racial Disparities in Stroke Risk Factors The Impact of Socioeconomic Status. Stroke. 2005;36:1507-11
13. Stewart JA, Dundas R, Howard RS, Rudd AG, Wolfe CD. Ethnic differences in incidence of stroke: prospective study with stroke register. BMJ. 1999;318:967-971
14. Morgan O, Baker A. Measuring deprivation in England and Wales using 2001 Carstairs scores. Health Stat Q. 2006;31:28-33
15. Zhang J, Yu KF. Whats the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690-1691
16. R Core Development Team. R, A Language and Environment for Statistical Computing. Vienna, Austria; 2008.
17. Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol. 2007;6:981-993
18. Stott DJ, Dewar RI, Garratt CJ, Griffith KE, Harding NJ, James MA, et al. Approaching the comprehensive management of Atrial Fibrillation: Evolution or revolution? Royal College of Physicians of Edinburgh website. http://www.rcpe.ac.uk/clinical-standards/standards/rcpe-Af- consensusstatement- 2012.pdf. Accessed January 7, 2013.
19. Sheppard JP, Singh S, Fletcher K, McManus RJ, Mant J. Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK. BMJ. 2012;345:4535.
20. Haynes B, Haines A. Barriers and bridges to evidence based clinical practice. BMJ. 1998;317:273-276
21. American College of Physicians. Guidelines for Medical Treatment for Stroke Prevention. Ann Intern Med. 1994;121:54-5
22. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 2000;160:41-46
23. Mant J, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GYH, Murray E. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study). Lancet. 2007;370:493-503
24. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ, Folsom AR. Incidence of atrial fibrillation in whites and African-Americans: The Atherosclerosis Risk in Communities study. Am Heart J. 2009;158:111-7
25. Shen AY, Chen W, Yao JF, Brar SS, Wang X, Go AS. Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation. CNS Drugs. 2008;22:815-825
26. Olesen JB, Lip GYH, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation. BMJ. 2011;342.
27. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110:2287-2292
28. Shen AY-J, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial-ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50:309-15
29. Szczepura A. Access to health care for ethnic minority populations. Postgrad Med J. 2005;81:141-147
30. Lane DA, Lip GY. Ethnic differences in hypertension and blood pressure control in the UK. QJM. 2001;94:391-396
31. Hull S, Dreyer G, Badrick E, Chesser A, Yaqoob MM. The relationship of ethnicity to the prevalence and management of hypertension and associated chronic kidney disease. BMC Nephrol. 2011;12:41.
32. Brooks EL, Preis SR, Hwang SJ, Murabito JM, Benjamin EJ, Kelly- Hayes M, et al. Health insurance and cardiovascular disease risk factors. Am J Med. 2010;123:741-747
33. Sims M, Maxwell R, Bauld L, Gilmore A. Short term impact of smokefree legislation in England: retrospective analysis of hospital admissions for myocardial infarction. BMJ. 2010;340:c2161.
34. Sever P, Beevers G, Bulpitt C, Lever A, Ramsay L, Reid J, et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ. 1993;306:983-987
35. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B; Guideline Development Group. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:d4891.
36. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-553
37. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyrl K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis. 1998;140:199-270
38. JBS 2: Joint British Societies guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(Suppl 5):1.